Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
Paulsen
Denise
D
Department of International Clinical Virology, GlaxoSmithKline Inc., 5 Moore Drive, Research Triangle Park, NC 27709, USA.
Elston
Robert
R
Snowden
Wendy
W
Tisdale
Margaret
M
Ross
Lisa
L
D002219:Carbamates; D024882:Drug Resistance, Viral; D005663:Furans; D008040:Genetic Linkage; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D061466:Lopinavir; D009154:Mutation / Q000235:genetics; D010641:Phenotype; D011744:Pyrimidinones / Q000494:pharmacology* / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D013449:Sulfonamides; D061466:Lopinavir; C095108:amprenavir